Latest / Healthcare Mysteries Uncovered
A mushroom-derived sleep drug halted at Phase 3 - because it looked like LSD
A mushroom-derived sleep drug halted at Phase 3 - because it looked like LSD
Sleep medicine’s promise and peril converge in one sentence: "Looks like LSD to me." Gaboxadol, a mushroom‑derived compound that increased slow‑wave sleep and raised the lethal-dose margin more than fourteenfold compared with muscimol, passed Phase 2 with clear clinical benefit - yet it was stopped before it reached patients. How did a drug that restored deep, restorative sleep vanish because it “looked” like something else?
In this episode, we tell the story of gaboxadol from lab bench to corporate decision…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.